|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib, a selective JAK1/JAK2 inhibitor, is the current first line therapy for myelofibrosis (MF), which reduces symptomatology and splenomegaly, but does not clearly modify disease course.
|
31778911 |
2020 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib (Rux), a Jak1/2 inhibitor, results in reduced spleen size and improvement in constitutional symptoms in the majority of patients with myelofibrosis (MF).
|
30962501 |
2020 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV).
|
31711337 |
2020 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms.
|
31201513 |
2019 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
|
30997748 |
2019 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Seven years after the approval of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis.
|
30675650 |
2019 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012.
|
30043249 |
2018 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert commentary: The most mature advances in treatment of myelofibrosis are the development of second-generation JAK1/2 inhibitors and improvements in expanding access to donors for transplantation.
|
30324817 |
2018 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Momelotinib is a Janus kinase 1/2 inhibitor in clinical development for the treatment of myelofibrosis.
|
29283448 |
2018 |
|
Myelofibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pacritinib (PAC), a multi-kinase inhibitor with specificity for JAK2, FLT3, and IRAK1 but sparing JAK1, has demonstrated clinical activity in MF with minimal myelosuppression.
|
29616317 |
2018 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib is a JAK1/2 inhibitor that may control myelofibrosis (MF)-related splenomegaly and symptoms and can be prescribed regardless of age.
|
30010187 |
2018 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib, a potent oral JAK1/JAK2 inhibitor remains the only Food and Drug Administration (FDA)-approved medicinal therapy for the treatment of MF.
|
29480036 |
2018 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this report, we discuss the clinical history, pathological evaluation, and genomics findings in a patient with JAK2-positive myelofibrosis who developed a secondary myelodysplasia after hematopoietic stem cell transplantation and JAK1/2 inhibitor treatment.
|
30097215 |
2018 |
|
Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One-hundred Mayo Clinic patients with high/intermediate-risk myelofibrosis (MF) received momelotinib (MMB; JAK1/2 inhibitor) between 2009 and 2010, as part of a phase 1/2 trial (NCT00935987); 73% harbored JAK2 mutations, 16% CALR, 7% MPL, 44% ASXL1, and 18% SRSF2.
|
29515114 |
2018 |
|
Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed 626 patients with MPN, including 69 with myelofibrosis receiving JAK1/2 inhibitors for lymphoma development.
|
29907599 |
2018 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib is a JAK1/2 inhibitor that is effective in managing symptoms and splenomegaly related to myelofibrosis (MF).
|
29189896 |
2018 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
|
27785927 |
2017 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The only approved JAK2 inhibitor for myelofibrosis is the dual JAK1 and JAK2 inhibitor, ruxolitinib.
|
28602585 |
2017 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing.
|
28500170 |
2017 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Purpose We evaluated the efficacy and safety of momelotinib, a potent and selective Janus kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients with myelofibrosis.
|
28930494 |
2017 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of note, ruxolitinib, a JAK1/2 inhibitor approved for the treatment of MF, had no inhibitory activity on this pathway.
|
28188131 |
2017 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we review novel therapeutic options for MF including the new JAK1/2 inhibitors, ruxolitinib based combination approaches as well as novel therapeutic agents.
|
28395559 |
2017 |
|
Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this open-label phase II study, we evaluated the efficacy and safety of three dose levels of INCB039110, a potent and selective oral JAK1 inhibitor, in patients with intermediate- or high-risk myelofibrosis and a platelet count ≥50×10<sup>9</sup>/L.
|
27789678 |
2017 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib, a JAK1/2 inhibitor, is currently the only drug approved for the treatment of patients with intermediate or high risk MF.
|
27882812 |
2017 |
|
Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two randomized clinical trials.
|
27740634 |
2017 |